Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Muhamed Baljevic

Showing results (41-50 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|May 24, 2008
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumorsSergey V Shmelkov, Jason M Butler, Andrea T Hooper, et al.
Acta Haematologica|September 16, 2016
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic LeukemiaMuhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, et al.
Blood Advances|April 12, 2024
Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepositoryMorgan L Shannon, J Brett Heimlich, Sydney Olson, et al.
Ejhaem|July 18, 2022
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myelomaCristina Gasparetto, Suzanne Lentzsch, Gary Schiller, et al.
British Journal of Haematology|September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN studyDouglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Cancer Cell|April 16, 2015
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemiaAlan H Shih, Yanwen Jiang, Cem Meydan, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal AntibodiesGary J Schiller, Brea C Lipe, Nizar J Bahlis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Ejhaem|December 5, 2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatmentMuhamed Baljevic, Cristina Gasparetto, Gary J Schiller, et al.
Pageof 6

Showing results (41-50 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|May 24, 2008
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumorsSergey V Shmelkov, Jason M Butler, Andrea T Hooper, et al.
Acta Haematologica|September 16, 2016
Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic LeukemiaMuhamed Baljevic, Bogdan Dumitriu, Ju-Whei Lee, et al.
Blood Advances|April 12, 2024
Clonal hematopoiesis and inflammation in the vasculature: CHIVE, a prospective, longitudinal clonal hematopoiesis cohort and biorepositoryMorgan L Shannon, J Brett Heimlich, Sydney Olson, et al.
Ejhaem|July 18, 2022
Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myelomaCristina Gasparetto, Suzanne Lentzsch, Gary Schiller, et al.
British Journal of Haematology|September 16, 2022
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN studyDouglas W Sborov, Muhamed Baljevic, Brandi Reeves, et al.
Cancer Cell|April 16, 2015
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemiaAlan H Shih, Yanwen Jiang, Cem Meydan, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 1, 2023
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal AntibodiesGary J Schiller, Brea C Lipe, Nizar J Bahlis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 18, 2023
Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 7, 2020
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in OncologyShaji K Kumar, Natalie S Callander, Kehinde Adekola, et al.
Ejhaem|December 5, 2022
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatmentMuhamed Baljevic, Cristina Gasparetto, Gary J Schiller, et al.
Pageof 6